Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 68
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 16
Results: 15
1
2
BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 65
- By:
- Publication type:
- Article
3
Anito-Cel Yields 100% Response Rate in R/R Myeloma.
- Published in:
- 2024
- By:
- Publication type:
- Proceeding
4
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 46
- By:
- Publication type:
- Article
5
Lawmaker Says Consumers Want and Need Price Transparency in Health Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 44
- By:
- Publication type:
- Article
6
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 43
- By:
- Publication type:
- Article
7
NEW ADVANCES IN Waldenström Macroglobulinemia.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 38
- By:
- Publication type:
- Article
8
MT-302 Utilizes Novel Mechanism of Action to Offer a Unique Treatment in Epithelial Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 32
- By:
- Publication type:
- Article
9
Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 28
- By:
- Publication type:
- Article
10
Novel Therapies and Combinations Augment Melanoma Treatment Arsenal.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 25
- By:
- Publication type:
- Article
11
Combination Regimens Make Their Mark in Frontline HCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 16
- By:
- Publication type:
- Article
12
Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2- Breast Cancer.
- Published in:
- 2024
- By:
- Publication type:
- Interview
13
FDA Digest.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 8
- Publication type:
- Article
14
THE ONGOING DEBATE: Progression-Free vs Overall Survival as the Primary Study Outcome in Therapeutic Cancer Trials.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 6
- By:
- Publication type:
- Article
15
Advancements Roll in Across Tumor Types as Conference Season Continues.
- Published in:
- OncologyLive, 2024, v. 25, n. 16, p. 4
- By:
- Publication type:
- Article